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Background-—US blood pressure reduction policies are largely restricted to hypertensive populations and associated benefits are
often estimated based on unrealistic interventions.
Methods and Results-—We used multivariable linear regression to estimate incidence rate differences contrasting the impact of 2
pragmatic hypothetical interventions to reduce coronary heart disease, stroke, and heart failure (HF) incidence: (1) a population-
wide intervention that reduced systolic blood pressure by 1 mm Hg and (2) targeted interventions that reduced the prevalence of
unaware, untreated, or uncontrolled blood pressure above goal (per Eighth Joint National Committee treatment thresholds) by 10%.
In the Atherosclerosis Risk in Communities Study (n=15 744; 45 to 64 years at baseline, 1987–1989), incident coronary heart
disease and stroke were adjudicated by physician panels. Incident HF was defined as the first hospitalization with discharge
diagnosis code of “428.” A 10% proportional reduction in unaware, untreated, or uncontrolled blood pressure above goal resulted in
4.61, 3.55, and 11.01 fewer HF events per 100 000 person-years in African Americans, and 3.77, 1.63, and 4.44 fewer HF
events per 100 000 person-years, respectively, in whites. In contrast, a 1 mm Hg population-wide systolic blood pressure
reduction was associated with 20.3 and 13.3 fewer HF events per 100 000 person-years in African Americans and whites,
respectively. Estimated event reductions for coronary heart disease and stroke were smaller than for HF, but followed a similar
pattern for both population-wide and targeted interventions.
Conclusions-—Modest population-wide shifts in systolic blood pressure could have a substantial impact on cardiovascular disease
incidence and should be developed in parallel with interventions targeting populations with blood pressure above goal. ( J Am
Heart Assoc. 2015;4:e002276 doi: 10.1161/JAHA.115.002276)
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D ecades of research have characterized the associationsbetween elevated blood pressure and a spectrum of
cardiovascular diseases (CVD) including cerebral vascular
disease, heart failure (HF), and coronary heart disease
(CHD).1–5 Among blood pressure–related deaths, published
estimates suggest that approximately one third of excess
CHD and all-cause mortality can be attributed to elevated
systolic blood pressure (SBP) at levels designated as nonhy-
pertensive,6,7 indicating that benefits achieved from
decreases in blood pressure are not limited to populations
with hypertension.8–12 Experimental and observational stud-
ies have also demonstrated the efficacy of lifestyle-based
blood pressure interventions, such as increased physical
activity and the Dietary Approaches to Stop Hypertension
(DASH) diet, for CVD prevention.13–17 This body of evidence
supports the development of population-wide interventions
to reduce blood pressure alongside interventions targeted
to populations with blood pressure above goal for CVD
reduction.18
Several authors have estimated the theoretical effects of
shifting the distribution of blood pressure, either by lowering the
mean population blood pressure or by decreasing the propor-
tion of the population classified as hypertensive.8,11,19–23
Framingham Heart Study investigators reported that a
2-mm Hg population-wide diastolic blood pressure (DBP)
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reduction was associated with an estimated 17% decrease in
the prevalence of hypertension, and a 6% reduction in the risk
of CHD.19 Other published studies examined CHD and stroke
events, but were conducted in predominantly white or
European populations and considered blood pressure treat-
ment guidelines no longer in use.8,19,20,23 The degree to which
modest population-wide blood pressure shifts may affect the
incidence of HF also remains unknown, as do the effects of
blood pressure shifts in African American populations,19 who
shoulder higher burdens of elevated blood pressure as well as
CVD than do white populations.1 Further, the majority of
published studies estimated cardiovascular benefits from
interventions that completely eliminated hypertension or
uncontrolled hypertension from the population, despite the
implausibility of such goals.24–26 Therefore, in a biracial,
population-based setting, we assessed the impact of 2 types
of pragmatic, hypothetical interventions on reducing the
incidence of CHD, stroke, and HF after full implementation: a
population-wide intervention that reduced SBP by 1 or
2 mm Hg and targeted interventions that achieved a 10%
reduction in the proportion of the population with unaware,
untreated, or uncontrolled blood pressure above goal.
Methods
Study Population
The Atherosclerosis Risk in Communities (ARIC) study is a
prospective, population-based investigation of the etiology
and natural history of CVD and its risk factors.27 From 1987
to 1989, ARIC investigators sampled 15 792 predominately
white and African American participants between the ages of
45 and 64 from 4 geographic regions in the United States:
Washington County, Maryland; suburban Minneapolis, Min-
nesota; Forsyth County, North Carolina; and Jackson, Missis-
sippi. The latter 2 communities contributed the majority of
African Americans to the cohort. Physical examinations and
standardized questionnaires were administered by trained
study personnel at baseline and during 4 follow-up examina-
tions. Cohort follow-up for identification and classification of
health outcomes is ongoing. The ARIC study obtained
institutional review board approval from all participating
institutions, and informed consent was obtained at each
study visit.
The following sequential exclusions were applied: partici-
pants who reported races other than African American or
white (n=48); participants missing information to classify
prevalent CHD, stroke, or HF or with prevalent CHD, stroke, or
HF from each respective analysis (CHD [n=1106], stroke
[n=315], or HF [n=1035]). Prevalent CHD was defined at
baseline by self-reported history of a physician-diagnosed
myocardial infarction, myocardial infarction identified by
electrocardiography, or prior coronary revascularization.
Prevalent stroke was defined as a self-reported history of
physician-diagnosed stroke.28 Prevalent HF was defined by
current use of medication prescribed for HF or manifest HF
defined by the Gothenburg criteria stage 3.29 After these
exclusions, a total of 14 638, 15 429, and 14 709 partici-
pants were available for the evaluation of incident CHD,
stroke, and HF, respectively. Follow-up time was calculated
from study enrollment to the first CHD, stroke, or HF event,
loss to follow-up, death, or December 31, 2011.
Exposure and Covariate Assessment
Seated blood pressure measurements were taken after a
5-minute rest using a random-zero sphygmomanometer; the
mean of the second and third readings from the baseline
examination was used for analysis. We used the 2014
Guidelines for the Management of High Blood Pressure from
the Eighth Joint National Committee (JNC 8) to identify
participants with blood pressure above goal: for participants
aged ≥60 years, SBP ≥150 mm Hg or a DBP ≥90 mm Hg; for
participants aged <60, SBP ≥140 mm Hg or a DBP
≥90 mm Hg.18 All study participants with blood pressure levels
below goal were classified as unexposed, irrespective of
medication use or history of hypertension, as they were
ineligible for interventions targeted to populations with blood
pressure above goal (Figure 1). Antihypertensive medication
use, race, age, and gender were assessed at study baseline.
Contemporary race-specific weighted proportions of una-
ware, untreated, and uncontrolled blood pressure above goal
in whites (n=1494, 11.9% blood pressure above goal: 40%
unaware; 14% untreated; 46% uncontrolled) and African
Americans (n=1004, 26.4% blood pressure above goal: 20%
unaware; 22% untreated; 58% uncontrolled) 45 to 64 years of
age were estimated from the National Health and Nutrition
Examination Survey (NHANES, 2009–12). Individuals with
hypertension who were aware and treated to JNC 8 treatment
goals were not included in the intervention group (Figure 1).
Outcome Ascertainment and Definitions
ARIC Study participants were interviewed annually by phone
and all hospitalizations and deaths during the preceding year
were identified, abstracted, and adjudicated according to
study criteria. Local hospital discharge records and vital
records were also surveyed to detect hospitalizations and
deaths of cohort participants. An incident CHD event was
defined as a validated definite or probable hospitalized
myocardial infarction, a definite CHD death, an unrecognized
myocardial infarction defined by electrocardiographic assess-
ment at study visits, or coronary revascularization.30 An
incident stroke event was defined as a first definite or
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probable hospitalized stroke occurring in a participant free of
a baseline history of physician-diagnosed stroke.28 Incident
HF was identified as the first occurrence of either a
hospitalization with discharge diagnosis code of 428.X in
any position or an I50 or 428 listed on a death certificate.31
Statistical Analysis
To estimate the number of incident CHD, stroke, and HF
events per 100 000 person-years (PY) potentially prevented
after a population-wide 1- or 2-mm Hg SBP reduction, we
used a least-squares linear regression approach32 to estimate
race-specific incidence rate differences (IRD) adjusted for age,
gender, and antihypertensive medication use. These models
provided estimates of the IRDs for CHD, stroke, or HF
associated with a 1 mm Hg decrement in SBP at study
baseline potentially achievable after lifestyle interventions
were fully implemented16,17,33–35; estimates for a 2-mm Hg
reduction were obtained by multiplying the SBP regression
coefficient by 2.
To evaluate interventions targeted to populations with
blood pressure above goal (Figure 1) after full implementa-
tion, we first estimated race-, gender-, and age- (in 5-year
increments) specific IRDs using the least-squares regression
approach32 for the association between blood pressure above
goal and incident CHD, stroke, or HF. Reduction on the
incidence rate after a 10% reduction in unaware, untreated, or
uncontrolled blood pressure above goal at study baseline was
then estimated in the ARIC study using the following equation:
IRDijk9(proportionlproportionm) where i, j, and k index race,
gender, and 5-year age categories, and proportion is the race-
specific proportion of blood pressure above goal estimated in
NHANES36 pre- (l subscript) and post (m subscript)- interven-
tion that shifted 10% of the proportion of the population with
unaware, untreated, or uncontrolled blood pressure above
goal to unexposed (ie, below goal blood pressure). Results
JNC 8 blood pressure goal
Individuals with blood pressure 
below JNC 8 blood pressure goal
Individuals with blood pressure 
above JNC 8 blood pressure goal
Blood pressure 
is below goal 
without 




and controlled to 
JNC 8 goal.  No 
intervention 
needed.
Aware of high 
blood 
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medication use. Eligible 
for intervention.
Figure 1. Diagram defining categories of blood pressure above and below the Eighth Joint National
Committee (JNC 8) treatment goal. Groups targeted by hypothetical interventions achieving 10%
proportional reductions in unaware, untreated, and uncontrolled blood pressure above the JNC 8 treatment
goal are shaded blue. JNC 8 indicates, 2014 Evidence-based Guidelines for the Management of High Blood
Pressure in Adults report from the Panel Appointed to the Eighth JNC.
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were presented per 100 000 PY and represented a special
case of the population attributable risk that considers partial,
rather than complete, elimination of the risk factor. Here, we
considered partial elimination of blood pressure above goal,
achieved after fully implementing interventions that
decreased the proportion of the population with unaware,
untreated, or uncontrolled blood pressure by 10%.19 Age- and
gender-specific results were then collapsed by race using a
case-load-weighted summation method,37,38 and 95% confi-
dence intervals (CIs) were obtained using bootstrapping.39
As a sensitivity analysis, we also estimated the impact of a
10% reduction in the total population with blood pressure
above goal. Hypothetical interventions that achieved a 5% and
20% reduction in the proportion of individuals with blood
pressure above goal as well as the proportions of individuals
with unaware, untreated, and uncontrolled blood pressure
above goal were also examined. Contemporary race-specific
population projections for the number of events prevented by
the population-wide and the targeted interventions were
calculated by multiplying the race-specific IRD estimates by
the race-specific total population aged 45 to 64 years without
a history of CHD, stroke, or HF, calculated by applying
weighted prevalence proportions estimated in NHANES
(2009–2012) (African Americans: CHD [n=40, weighted
prevalence proportion 4.0%], stroke [n=62, weighted preva-
lence proportion 6.1%], HF [n=38, weighted prevalence
proportion 3.8%]; whites: CHD [n=70, weighted prevalence
proportion 3.3%] stroke [n=55, weighted prevalence propor-
tion 2.2%], HF [n=42, weighted prevalence proportion 3.8]) to
the 2010 US census population. All statistical analyses were
performed with SAS 9.3 software (SAS Institute, Cary, NC)
and Stata12 (StataCorp, College Station, TX).
Results
At study baseline, a maximum of 15 744 (27% African
American) ARIC cohort members were available for analysis
(Table 1). African Americans were more likely to be female
and on average to have higher estimated SBP and diastolic
blood pressure than white participants. African American
individuals were over twice as likely to have blood pressure
above goal and to report the use of antihypertensive
medications. Although African Americans were slightly
younger at baseline, they contributed on average 1.2 years
less person time through 2011 than did whites.
Over a mean 20 years of follow-up, 1803 incident CHD
events, 1147 incident stroke events, and 2537 incident
HF events were identified (Tables 1 and 2). Age-adjusted
incidence rates for CHD, stroke, and HF were higher among
African Americans than whites. The discrepancy by race was
especially apparent for HF, where estimated incidence rates
were 1193/100 000 PY among African Americans but 786/
100 000 PY among whites.
A population-wide hypothetical intervention that achieved
an overall 1 mm Hg decrement in SBP at study baseline after
Table 1. Baseline Characteristics of the ARIC Study Cohort







Prevalent CHD, N (%) 171 (4.1) 594 (5.3)
Prevalent stroke, N (%) 53 (1.3) 52 (0.5)
Prevalent HF, N (%) 296 (7.1) 455 (4.0)
Mean follow-up in y, (SD) 19.1 (6.5) 20.3 (5.6)
Mean age in y, (SD) 53.6 (5.8) 54.4 (5.7)
Female, N (%) 2635 (61.8) 6050 (52.7)
Reported antihypertensive use, N (%) 1728 (51.5) 2271 (22.7)
Mean systolic blood pressure,
mm Hg (SD)
128.9 (21.6) 118.5 (17.0)
Mean diastolic blood pressure,
mm Hg (SD)
79.7 (12.3) 71.5 (10.1)
Blood pressure categories*
Blood pressure below JNC 8 goal,
N (%)
3031 (71.2) 10 285 (89.7)
Blood pressure above JNC 8 goal,
N (%)
1229 (28.8) 1186 (10.3)
Above JNC 8 goal and
unaware
332 (27.0) 419 (35.3)
Above JNC 8 goal, aware but
untreated
272 (22.1) 258 (21.8)
Above JNC 8 goal, treated, but
uncontrolled
608 (49.5) 487 (41.1)
ARIC indicates Atherosclerosis Risk in Communities Study; CHD, coronary heart disease;
HF, heart failure; JNC, Joint National Committee.
*Blood pressure above goal, blood pressure values that exceed thresholds for
management of blood pressure defined by JNC 8; blood pressure below goal, blood
pressure values below thresholds for management of blood pressure defined by JNC 8.
Table 2. Incident CHD, Stroke, and HF Events and Incidence







No. Events IR* No. Events IR*
Incident CHD 554 711 1249 563
Incident Stroke 458 585 689 301
Incident HF 857 1193 1680 786
ARIC indicates Atherosclerosis Risk in Communities Study; CHD, coronary heart disease;
HF, heart failure; IR, incidence rate; N, events, number of events; n, maximum number of
individuals before exclusions.
*IR per 100 000 person-years.
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full implementation yielded a greater estimated number of
preventable events per 100 000 PY for HF (Figure 2A,
Table 3), than for CHD and stroke. Notably, the estimated
benefits from modest population-wide decrements in SBP were
consistently greater for African Americans than for whites; the
greatest difference by race was observed for incident HF, for
which a 1 mm Hg population-wide decrement in SBP pre-
vented 7.0 additional events per 100 000 PY in African
Americans when compared to whites. If applied nationwide, a
hypothetical 1 mm Hg shift in SBP among African American
and white US populations aged 45 to 64 years was estimated
to prevent 9338 incident HF events, 6210 incident CHD
events, and 3761 incident stroke events annually (Table 4). As
expected, the hypothetical intervention achieving the larger
SBP reduction of 2 mm Hg was associated with larger
reductions in the incidence of CHD, stroke, and HF for both
racial groups (Figure 2B, Tables 3 and 4).
We then contrasted the hypothetical population-wide SBP
reduction with interventions targeted to populations with
blood pressure above goal that achieved a 10% proportional
reduction in unaware, untreated, or uncontrolled blood
pressure. For example, before intervention, 26.4% of African
Americans and 11.9% of whites 45 to 64 years of age were
classified as having blood pressure above goal (NHANES
2009–2012; Table 5); we therefore evaluated a targeted
intervention that achieved a 10% proportional decrease in
unaware blood pressure above goal (ie, 20% to 18% among
African Americans and 40% to 36% among whites, respec-
tively) resulting in post-intervention proportions of blood
pressure above goal of 25.84% for African Americans and
11.41% for whites (Table 5). Similar to results from the
population-wide SBP interventions, 10% proportional reduc-
tions in unaware, untreated, or uncontrolled blood pressure
above goal produced the largest reduction in events for HF,
the magnitude of which varied by race (Table 6, Figure 3).
Specifically, a 10% proportional reduction in unaware,
untreated, or uncontrolled blood pressure above goal at study
baseline resulted in 4.61 (95% CI: 2.50–7.36), 3.55 (95% CI:
1.79–5.73), and 11.01 (95% CI: 6.17–17.52) fewer HF events
per 100 000 PY, respectively, in African Americans and 3.77
(95% CI: 1.88–6.51), 1.63 (95% CI: 0.65–3.04), and 4.44 (95%
CI: 2.49–6.81) fewer HF events per 100 000 PY, respectively,
A
B
Figure 2. Incidence rate differences in CHD, stroke, and HF per
100 000 person-years associated with a 1 mm Hg (A) and a
2 mm Hg (B) reduction in SBP in African Americans (black circles)
and whites (white squares), the ARIC cohort study, 1987–2011. A,
Population-wide 1 mm Hg reduction in systolic blood pressure. B,
Population-wide 2 mm Hg reduction in systolic blood pressure.
ARIC indicates Atherosclerosis Risk in Communities; CHD, coronary
heart disease; HF, heart failure; SBP, systolic blood pressure.
Table 3. Estimated Events Reduced for CHD, Stroke, and HF From 2 Population-Wide Hypothetical Blood Pressure Reduction




Events Reduced by Population-Wide
Intervention (95% CI)
No. Events
Events Reduced by Population-Wide
Intervention (95% CI)
1-mm Hg Decrease* 2-mm Hg Decrease* 1-mm Hg Decrease* 2-mm Hg Decrease*
CHD 554 13.5 (8.8–18.2) 27.0 (17.5–36.4) 1249 9.0 (6.3–11.6) 17.9 (12.6–23.2)
Stroke 458 12.1 (7.9–16.3) 24.2 (15.8–32.6) 689 4.8 (2.9–6.6) 9.6 (5.9–13.3)
HF 857 20.3 (14.4–26.2) 40.6 (28.8–52.4) 1680 13.3 (10.4–16.3) 26.6 (20.7–32.5)
ARIC indicates Atherosclerosis Risk in Communities Study; CHD, coronary heart disease; HF, heart failure.
*Per 100 000 person-years.
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in whites (Table 6, Figure 3). If 10% proportional reductions in
unaware, untreated, or uncontrolled blood pressure above
goal were achieved nationwide in African Americans and white
populations aged 45 to 64, 2200, 1017, and 3164 fewer
incident HF events, respectively, could be prevented annually;
1390, 650, and 2016 incident CHD and 962, 497, and 1505
stroke events would be prevented annually given 10%
proportional reductions in unaware, untreated, or uncontrolled
blood pressure above goal, respectively (Table 7).
Sensitivity analyses examining 5% to 20% proportional
reductions in the total population with blood pressure above
goal target a larger segment of the population with blood
pressure above goal and demonstrated considerably larger
reductions in CHD, stroke, and HF events than interventions
targeting unaware, untreated, or uncontrolled blood pressure
above JNC 8 goals (Tables 7 and 8). Heterogeneity by race for
interventions achieving reductions in the total population with
blood pressure above goal was also observed, with event
reductions for African Americans approximately twice as large
as event reductions for whites.
Discussion
Predicted benefits from blood pressure reductions estimated
in a biracial, population-based cohort showed that a modest
population-wide 1 mm Hg decrement in SBP could prevent
substantial numbers of cardiovascular events. Interventions
targeted to the population with blood pressure above goal
that achieved a 10% proportional reduction in unaware,
untreated, or uncontrolled blood pressure also achieved
meaningful cardiovascular event reductions, but were of
smaller magnitude. Of the 3 CVD outcomes investigated,
hypothetical interventions that decreased SBP or blood
pressure above goal had the greatest estimated impact on
reducing HF incidence. With both intervention types, the
estimated benefits of lowering blood pressure on CVD events
were greater for African Americans compared to whites.
Decades of research have demonstrated that the medical
management of blood pressure among hypertensive popula-
tions is effective in reducing the risk of CVD and addresses
the medical responsibility to lower the risk of clinical events
among those at highest risk.7,40–42 Accordingly, clinical and
public health efforts to improve hypertension awareness,
treatment, and control have translated into cardioprotective
benefits, as shown between 1998 and 2008 when the mean
SBP for US adults with hypertension declined by 10
mm Hg.40 However, declines in SBP were largely limited to
hypertensive populations, as the average SBP for the entire
US population changed little over the same time span.40
The large cardioprotective benefits associated with the
medical management of blood pressure led earlier studies to
evaluate the hypothetical impact of 100% elimination of
hypertension on the incidence of CVD through metrics like the
population-attributable fraction.24,26 For reference, our results
suggested that if 100% of aware and treated blood pressure
above goal was controlled among African American and
Table 4. Estimated Events Reduced Annually for CHD, Stroke, and HF From 2 Population-Wide Hypothetical Blood Pressure







1-mm Hg Decrease 2-mm Hg Decrease 1-mm Hg Decrease 2-mm Hg Decrease
CHD 8 701 219 1175 2349 55 946 031 5035 10 070
Stroke 8 501 707 1029 2057 56 575 526 2733 5465
HF 8 700 428 1766 3532 56 930 452 7572 15 144
CHD indicates coronary heart disease; HF, heart failure.
*Total 2010 US census race specific populations aged 45 to 64 (African Americans n=9 042 518, whites n=57 864 260) were used to calculate the population with prevalent CHD, stroke
or HF excluded, respectively, using weighted prevalence proportions for history of CHD, stroke, and HF by above-goal blood pressure.
Table 5. Proportion of African American and White NHANES Participants Aged 45 to 64 Years With Blood Pressure Above JNC 8
Goal Before and After Targeted Interventions Improving Unaware, Untreated, and Uncontrolled Blood Pressure by 10%, 2009–2012
Race
Proportion of Participants With Blood Pressure Above Goal
Before
Intervention
After 10% Reduction in Proportion
of Unaware Blood Pressure Above Goal
After 10% Reduction in Proportion of
Untreated Blood Pressure Above Goal
After 10% Reduction in Proportion of
Uncontrolled Blood Pressure Above Goal
African Americans 26.36 25.84 25.78 24.82
Whites 11.88 11.41 11.71 11.33
JNC indicates Joint National Committee; NHANES, National Health and Nutrition Examination Survey.
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whites aged 45 to 64 years of age, 20 154 CHD events
could be prevented annually in the United States, consistent
with recently published estimates using the JNC 8 guide-
lines.24 Despite considerable clinical and public health efforts
to improve hypertension management, no historical precedent
is available for achieving 100% control; instead, nationally
representative estimates suggested that 43.5% of adults
with treatment-eligible hypertension are not treated to goal.43
As an alternative, we estimated event reductions achieved by
modest, but plausible decreases in the proportion of the
population classified as having unaware, untreated, and
uncontrolled blood pressure above goal. As expected, full
implementation of interventions that achieved 10% changes in
unaware, untreated, and uncontrolled blood pressure above
goal were estimated to prevent considerably fewer CVD
events than fully implemented interventions assuming 100%
elimination of blood pressure above goal. This discrepancy
reflects the proportion of the population for whom we assume
a successful intervention. For example, in a population of
100 000 (prevalence of blood pressure above goal 20%;
composed of 40% unaware, 14% aware but untreated, and
46% aware treated but uncontrolled), a successful interven-
tion that reduced uncontrolled blood pressure above goal by
10% would target 920 people compared to the substantially
larger population of 20 000 people targeted by an interven-
tion assuming 100% elimination of blood pressure above goal.
Figure 3. IRDs for CHD, stroke and HF per 100 000 person-
years associated with 10% proportional reductions in unaware
(circle), untreated (squares), or uncontrolled (triangles) blood
pressure above JNC 8 treatment goal in African American (black
symbols) and white (white symbols) ARIC participants, 1987–
2011. ARIC indicates Atherosclerosis Risk in Communities; CHD,
coronary heart disease; HF, heart failure; IRDs, incidence rate
differences; JNC, Joint National Committee.
Table 7. Estimated Events Reduced for CHD, Stroke, and HF From Hypothetical Targeted BP Reduction Interventions, by Race,
2010 US Census Population Aged 45 to 64
Event Type BP Category
Events Reduced Annually by Interventions Achieving Reductions in BP Above Goal
Population (N) 10% Proportional Reduction
African American* White* African American White
Hypothetical intervention to reduce unaware BP above goal
CHD BP above JNC 8 goal 8 701 219 55 946 031 211 1169
Stroke BP above JNC 8 goal 8 501 707 56 575 526 213 749
HF BP above JNC 8 goal 8 700 428 56 930 452 335 1865
Hypothetical intervention to reduce untreated BP above goal
CHD BP above JNC 8 goal 8 701 219 55 946 031 246 404
Stroke BP above JNC 8 goal 8 501 707 56 575 526 238 259
HF BP above JNC 8 goal 8 700 428 56 930 452 373 644
Hypothetical intervention to reduce uncontrolled BP above goal
CHD BP above JNC 8 goal 8 701 219 55 946 031 654 1362
Stroke BP above JNC 8 goal 8 501 707 56 575 526 632 873
HF BP above JNC 8 goal 8 700 428 56 930 452 991 2173
Hypothetical intervention to reduce total population with BP above goal
CHD BP above JNC 8 goal 8 701 219 55 946 031 1121 2934
Stroke BP above JNC 8 goal 8 501 707 56 575 526 1083 1880
HF BP above JNC 8 goal 8 700 428 56 930 452 1699 4682
BP indicates blood pressure; CHD, coronary heart disease; HF, heart failure; JNC, Joint National Committee.
*Total 2010 US census race-specific populations aged 45 to 64 (African Americans n=9 042 518, whites n=57 864 260) were used to calculate the population with prevalent CHD,
stroke, or HF excluded, respectively, using weighted prevalence proportions for history of CHD, stroke, and HF by above-goal BP.
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Targeted interventions and population-wide interventions
are complementary, and it is admittedly difficult to compare
the 2 since the clinical and public health prevention and
control strategies, their associated costs, and target popula-
tions differ considerably. Targeted efforts to improve the
management of hypertension have resulted in relatively low
levels of unaware, untreated, and uncontrolled hypertension,
particularly after the realignment introduced by the 2014 JNC
8 guideline for the management of high blood pressure.40,43
Interventions targeted to populations with blood pressure
above goal will therefore become less effective in lowering
CVD incidence as blood pressure awareness, treatment, and
control continue to improve, limiting the target population.40
Conversely, population-wide lifestyle approaches to blood
pressure reduction, as encouraged by the 2013 AHA/ACC
Guideline on Lifestyle Management to Reduce Cardiovascular
Risk, have been successful in reducing CVD across a wide
range of blood pressures.15,16,44 For example, prior popula-
tion-wide intervention studies of salt reduction demonstrated
decreases in morbidity, mortality, and healthcare costs with
as little as 1 g less of salt per day (equivalent to 1/6 of a
teaspoon)15 and are feasible, as evidenced by recent dietary
salt reduction programs in the United Kingdom focused on
manufactured food that decreased mean sodium content in
the food supply by 7%.13 Other potential lifestyle interventions
to reduce blood pressure include increasing physical activ-
ity,45,46 reducing weight,47 and improving overall diet qual-
ity.46 Further studies are needed to inform safety48,49 and
selection of the most cost-effective population-wide interven-
tions in the United States to decrease SBP.
Our results highlight the potential of population-wide SBP
reduction approaches to complement interventions targeted to
clinically defined populations with blood pressure above goal.
Interventions targeting the US white populations with uncon-
trolled blood pressure would need to achieve approximately a
30% proportional reduction in uncontrolled blood pressure in
order to achieve event reduction comparable to those
estimated for population-wide interventions that achieve a 1-
mm Hg shift in SBP. African American populations, among
whom blood pressure elevation occurs at earlier ages and show
elevated rates of CVD in the United States,1,40 likely would reap
the greatest benefits of population-wide and targeted above
goal blood pressure interventions, particularly for uncontrolled
blood pressure, suggesting that both types of interventions
have potential for reducing these persistent health disparities.
The strengths of this study include the use of a large,
biracial cohort with high retention and quality assurance
protocols over an average of 20 years of follow-up. There also
are several limitations that deserve consideration. First, the
ARIC cohort may not be fully generalizable to the US
population, particularly for African Americans participants,
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Forsyth County, North Carolina; other US minority groups
were not represented in this study. The ARIC study was also
restricted to participants aged 45 to 64 years at study
baseline. Additionally, several studies suggest that the
national incidence of CVD events has changed since the
1980s, with the incidence of CHD and stroke declining and
the incidence of HF increasing,1,50,51 which may over- or
underestimate the number of events reduced by population-
wide and targeted blood pressure interventions. Secondly, we
assumed the same incidence rate reduction when calculating
the number of events that could be prevented from interven-
tions that targeted unaware, untreated, and uncontrolled
blood pressure above goal. We also estimated separate
intervention effects, for unaware, untreated, and uncontrolled
blood pressure above goal, although in practice, these
interventions would likely be promoted in combination and
associated with target-specific IRDs. Third, if future guideli-
nes, following the results of the Systolic Blood Pressure
Intervention Trial (SPRINT), reduce the thresholds for treat-
ment or goal for blood pressure control, interventions that
reduce untreated or uncontrolled blood pressure could result
in substantially larger reductions in events.52 Despite these
limitations, few studies have evaluated pragmatic blood
pressure interventions and even fewer have included African
Americans, who shoulder historic blood pressure and CVD
disparities, positioning this study to contribute increased
understanding of the population management of elevated
blood pressure.
In conclusion, population-wide reductions in SBP of modest
magnitude are predicted to have a substantial impact on CVD
prevention and should be developed in parallel with interven-
tions targeted to populations with blood pressure above goal.
As advocated by many primary prevention statements,33,53,54
the management of blood pressure in adults should not be
limited to those classified as hypertensive, but rather extend
to the majority of the populations below hypertension
treatment thresholds. Omitting such individuals leaves a large
segment of the population at increased risk of cardiovascular
events and constrains the ability of clinicians and public
health practitioners to reduce the societal burden of blood
pressure–related CHD, stroke, and HF.
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